1446359-40-5Relevant academic research and scientific papers
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
Nakai, Takashi,Perl, Nicholas R.,Barden, Timothy C.,Carvalho, Andrew,Fretzen, Angelika,Germano, Peter,Im, G-Yoon J.,Jin, Hong,Kim, Charles,Lee, Thomas W.-H.,Long, Kimberly,Moore, Joel,Rohde, Jason M.,Sarno, Renee,Segal, Chrissie,Solberg, Erik O.,Tobin, Jenny,Zimmer, Daniel P.,Currie, Mark G.
supporting information, p. 465 - 469 (2016/06/01)
In recent years, soluble guanylate cyclase (sGC, EC 4.6.1.2) has emerged as an attractive therapeutic target for treating cardiovascular diseases and diseases associated with fibrosis and end-organ failure. Herein, we describe our design and synthesis of
2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS
-
Page/Page column 166, (2013/07/19)
2-Benzyl, 3 - (pyrimidin- 2 -YL) substituted pyrazoles are described. They are useful as stimulators of sGC, particularly NO - independent, heme - dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
